Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-22T08:43:29.994Z Has data issue: false hasContentIssue false

Authors' reply

Published online by Cambridge University Press:  02 January 2018

P. Vestergaard
Affiliation:
Mood Disorders Research Unit, Aarhus University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark
R. W. Licht
Affiliation:
Mood Disorders Research Unit, Aarhus University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2000 The Royal College of Psychiatrists 

Gracious & Falodun find that our study of mortality in affective disorder patients commenced on lithium (Reference Brodersen, Licht and VestergaardBrodersen et al, 2000) paints an unfairly negative picture of lithium's efficacy. They object to our intention-to-treat analysis of all patients commenced on lithium irrespective of compliance, which showed a significantly elevated standardised mortality ratio (SMR) of 2.5. They suggest that we should have compared compliant with non-compliant patients and with the general population, as did Kallner et al (Reference Kallner, Lindellius and Petterson2000).

Kallner et al actually reported — even in patients compliant with lithium — that mortality in general (SMR=1.6) and suicide in particular (SMR=14.0) were significantly elevated. They also found that mortality was even higher in non-compliant patients, a result which may very well be valid. However, comparison of compliant with non-compliant patients introduces a considerable selection bias, since patients are not randomly allocated to the two groups. Rather, patients with comorbidity, such as drug and alcohol misuse and other predictors of negative outcome (Reference Vestergaard, Licht and BrodersenVestergaard et al, 1998) select themselves to the non-compliant patient group. Therefore, a finding that non-compliant patients fare worse than compliant patients may testify only to the existence of negative predictor variables among patients who were non-compliant, instead of supporting the efficacy of lithium treatment. Neither our study nor Kallner et al's allow conclusions as to whether or not lithium has specific antisuicidal effects exceeding what can be inferred from its ability to prevent recurrent illness episodes in affective disorder patients.

The efficacy of long-term prophylactic treatment with lithium has been questioned frequently (Reference MoncrieffMoncrieff, 1995). We believe, as apparently do Gracious & Falodun, that despite its shortcomings lithium is a very helpful tool in the psychiatric armamentarium. Arguments that support the efficacy (or inefficacy) of long-term lithium treatment should, however, rest on sound scientific evidence.

References

Brodersen, A., Licht, R. W., Vestergaard, P., et al (2000) Sixteen-year mortality in patients with affective disorder commenced on lithium. British Journal of Psychiatry, 176, 429433.CrossRefGoogle ScholarPubMed
Kallner, G., Lindellius, R., Petterson, U., et al (2000) Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it. Pharmacopsychiatry, 33, 813.Google Scholar
Moncrieff, J. (1995) Lithium revisited. A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. British Journal of Psychiatry, 167, 569574.CrossRefGoogle ScholarPubMed
Vestergaard, P., Licht, R. W., Brodersen, A., et al (1998) Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatrica Scandinavica, 98, 310315.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.